	US 12,083,192 B2
	Methods for treatment of patients with myelodysplastic syndromes
Mark Berger, New York, NY (US)
Assigned to Actinium Pharmaceuticals, Inc., New York, NY (US)
Appl. No. 16/766,009
Filed by Actinium Pharmaceuticals, Inc., New York, NY (US)
PCT Filed Dec. 4, 2018, PCT No. PCT/US2018/063795 § 371(c)(1), (2) Date May 21, 2020, PCT Pub. No. WO2019/113031, PCT Pub. Date Jun. 13, 2019.
Claims priority of provisional application 62/594,259, filed on Dec. 4, 2017.
Prior Publication US 2020/0276339 A1, Sep. 3, 2020
Int. Cl. A61K 51/10 (2006.01); A61K 31/10 (2006.01); A61K 31/198 (2006.01); A61K 31/675 (2006.01); A61K 31/7076 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 16/28 (2006.01); C12Q 1/6886 (2018.01); A61K 39/00 (2006.01)

CPC A61K 51/1033 (2013.01) [A61K 31/10 (2013.01); A61K 31/198 (2013.01); A61K 31/675 (2013.01); A61K 31/7076 (2013.01); A61K 51/1069 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 16/2803 (2013.01); C12Q 1/6886 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C12Q 2600/156 (2013.01)]

18 Claims

1. A method of treating a hematologic malignancy in a subject comprising administering to the subject an effective amount of an anti-CD33 targeting agent, wherein the subject has a complex karyotype or a p53 mutation,

wherein the anti-CD33 targeting agent comprises a radiolabel selected from the group consisting of ¹³¹I, ¹²⁵I, ¹²³I, ⁹⁰Y, ¹⁷⁷Lu, ¹⁸⁶Re, ¹⁸⁸Re, ⁸⁹Sr, ¹⁵³Sm, ³²p, ²²⁵Ac, ²¹³Bi, 213Po, 211At, 212Bi, ²¹³Bi, ²²³Ra, ²²⁷Th, ¹⁴⁹Tb, ¹³⁷Cs, ²¹²Pb, and ¹⁰³Pd, and

wherein the hematologic malignancy comprises myelodysplastic syndrome (MDS), multiple myeloma (MM), acute myeloid leukemia (AML), myeloproliferative neoplasm, or a combination thereof, and

wherein the anti-CD33 targeting agent comprises lintuzumab, gemtuzumab, or vadastuximab;

and wherein the effective amount of the anti-CD33 targeting agent is an amount sufficient to induce myeloconditioning, or an amount sufficient to induce myeloabation.